Shardul Amarchand Mangaldas Advises Nephrocare Health Services on Initial Public Offering Worth Approximately US$ 95.99 Million

Shardul Amarchand Mangaldas & Co. advised Nephrocare Health Services Limited (Nephroplus) on its initial public offering. The transaction comprised an initial public offering aggregating to approximately US$ 95.99 million (₹ 8,710.48 million), consisting of a fresh issue of ₹ 3,534.05 million and an offer for sale of ₹ 5,176.43 million. SAM acted as legal counsel to Nephroplus on Indian law aspects of the transaction, advising on drafting and regulatory compliance for the IPO, coordinating with multiple domestic and international stakeholders, and supporting the company through the prospectus filing and listing process. Shardul Amarchand Mangaldas & Co. represented Nephrocare Health Services Limited (Nephroplus) with a team composed by: Prashant Gupta, National Practice Head – Capital Markets; Devi Prasad Patel, Partner; Divya Dhawan, Associate; Satakshi N. Dixit, Associate; and Arjun Bhatia, Associate.

Shardul Amarchand Mangaldas Advises Nephrocare Health Services on Initial Public Offering Worth Approximately US$ 95.99 Million

Read the full story